Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$2.20 USD
-0.34 (-13.39%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $2.27 +0.07 (3.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.20 USD
-0.34 (-13.39%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $2.27 +0.07 (3.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Energous (WATT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Energous (WATT) delivered earnings and revenue surprises of 12.50% and 22.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ADT (ADT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ADT (ADT) delivered earnings and revenue surprises of 20% and 3.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 6.67% and 32.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for February 15th
by Zacks Equity Research
ATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022
Applied DNA Sciences (APDN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -231.58% and 2.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Napco (NSSC) Lags Q2 Earnings Estimates
by Zacks Equity Research
Napco (NSSC) delivered earnings and revenue surprises of -66.67% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Applied DNA Sciences (APDN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson Controls (JCI) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson Controls (JCI) delivered earnings and revenue surprises of 1.89% and 1.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -53.13% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -91.67% and -50.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 29th
by Zacks Equity Research
ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Applied DNA Sciences (APDN)
by Zacks Equity Research
Applied DNA Sciences (APDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Applied DNA Sciences (APDN) Moves 13.2% Higher: Will This Strength Last?
by Zacks Equity Research
Applied DNA Sciences (APDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Applied DNA Sciences (APDN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -12.73% and 15.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for January 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Applied DNA Sciences (APDN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -38.98% and -55.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Corporate News for May 15, 2020
by Zacks Equity Research
Companies In The News Are: APDN, CSCO, IMUX, VRTU